Ponaxen is identified on this website as a product containing ponatinib in stated 15 mg and 45 mg strengths. Product-specific manufacturing and authorization information requires verification.
Ponatinib is a kinase inhibitor that targets BCR::ABL1, the abnormal tyrosine kinase associated with Philadelphia chromosome-positive leukemias. It also inhibits other kinases, including members of the SRC family and selected additional signaling kinases.
Product identity
| Attribute | Information |
|---|---|
| Product | Ponaxen |
| Generic name | Ponatinib |
| Stated strengths | 15 mg, 45 mg |
| Route | Oral, subject to product documentation |
| Drug class | Tyrosine kinase inhibitor |
| Main disease area | CML and Ph+ ALL |
| Reference product | ICLUSIG |
| Original developer | ARIAD Pharmaceuticals |
| Specific Ponaxen manufacturer | Everest Pharmaceuticals Ltd. |
Ponatinib and ICLUSIG
ICLUSIG is the established reference product containing ponatinib. The original U.S. application was submitted by ARIAD Pharmaceuticals, and the FDA records initial approval in December 2012.
Ponaxen should not automatically be described as ICLUSIG or as an identical formulation. A product relationship must be established through regulatory and manufacturer documentation.
Why ponatinib is clinically distinctive
Ponatinib was developed to inhibit BCR::ABL1, including the T315I mutation, which can produce resistance to several earlier BCR::ABL1 tyrosine kinase inhibitors. Current U.S. labeling includes T315I-positive CML and T315I-positive Ph+ ALL in specified circumstances.
Because ponatinib has significant vascular and cardiovascular risks, treatment requires careful clinical assessment and monitoring.
Regulatory caution
U.S. and European indications are not necessarily identical. Current EMA information includes adult CML and Ph+ ALL indications and pediatric chronic-phase CML from six years of age, while the current U.S. label has its own specific criteria.